These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
272 related items for PubMed ID: 36649528
1. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales. Ozyurt OK, Tufanoglu P, Cetinkaya O, Ozhak B, Yazisiz H, Ongut G, Turhan O, Ogunc D. Clin Lab; 2023 Jan 01; 69(1):. PubMed ID: 36649528 [Abstract] [Full Text] [Related]
2. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates]. Hoşbul T, Aydoğan CN, Kaya S, Bedir O, Gümral R, Albay A. Mikrobiyol Bul; 2022 Apr 01; 56(2):218-229. PubMed ID: 35477226 [Abstract] [Full Text] [Related]
3. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D, Stone GG. BMC Infect Dis; 2021 Jun 23; 21(1):600. PubMed ID: 34162341 [Abstract] [Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC, Stone GG. Ann Clin Microbiol Antimicrob; 2020 Apr 01; 19(1):14. PubMed ID: 32238155 [Abstract] [Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017. Stone GG, Seifert H, Nord CE. Int J Antimicrob Agents; 2020 Sep 01; 56(3):106045. PubMed ID: 32522673 [Abstract] [Full Text] [Related]
13. In vitro activity of ceftazidime-avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020. Stone G, Wise M, Utt E. Microbiol Spectr; 2024 Mar 05; 12(3):e0147323. PubMed ID: 38329363 [Abstract] [Full Text] [Related]
14. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. Karlowsky JA, Bouchillon SK, Benaouda A, Soraa N, Zerouali K, Mohamed N, Alami T, Sahm DF. J Glob Antimicrob Resist; 2022 Sep 05; 30():23-30. PubMed ID: 35447385 [Abstract] [Full Text] [Related]
17. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates. Teo JQ, Chang HY, Tan SH, Tang CY, Ong RT, Ko KKK, Chung SJ, Tan TT, Kwa AL. Microbiol Spectr; 2023 Jun 15; 11(3):e0100223. PubMed ID: 37184408 [Abstract] [Full Text] [Related]
18. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019. Tuan Soh TS, Salvinder S, Chen VSY. Med J Malaysia; 2022 Mar 15; 77(2):174-184. PubMed ID: 35338624 [Abstract] [Full Text] [Related]
19. In-vitro activities of essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021. Wu Y, Chen J, Zhang G, Li J, Wang T, Kang W, Zhang J, Sun H, Liu Y, Xu Y. Int J Antimicrob Agents; 2024 Nov 15; 64(5):107341. PubMed ID: 39304121 [Abstract] [Full Text] [Related]